| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | TTG2; LMO-2; RBTN2; RHOM2; RBTNL1 |
| Entrez GeneID | 4005 |
| WB Predicted band size | Calculated MW: 18 kDa; Observed MW: 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human LMO2 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于LMO2抗体的3篇参考文献，包含文献名称、作者及摘要内容概括：
1. **文献名称**：*LMO2蛋白在T细胞急性淋巴细胞白血病中的表达及临床意义*
**作者**：Van Vlierberghe P, et al.
**摘要**：该研究通过免疫组化分析发现，LMO2抗体在T-ALL患者样本中特异性识别LMO2蛋白，其异常高表达与患者预后不良相关，提示LMO2可作为白血病分子标志物。
2. **文献名称**：*LMO2在弥漫大B细胞淋巴瘤中的诊断应用*
**作者**：Natkunam Y, et al.
**摘要**：研究利用LMO2抗体进行免疫组化染色，证实LMO2在生发中心型弥漫大B细胞淋巴瘤(GCB-DLBCL)中高表达，支持其作为区分DLBCL亚型的可靠标记物。
3. **文献名称**：*LMO2调控造血干细胞发育的分子机制*
**作者**：McCormack MP, et al.
**摘要**：通过抗体介导的蛋白质互作实验，揭示了LMO2在造血干细胞中与TAL1等转录因子形成复合物，调控关键基因表达，影响造血分化过程。
(如需更多文献，可进一步补充。)
The LMO2 antibody is a crucial tool in studying the LIM-only protein 2 (LMO2), a key transcriptional regulator involved in hematopoietic development and oncogenesis. LMO2. part of the LIM-domain protein family, lacks DNA-binding capacity but acts as a scaffolding protein to mediate interactions between transcription factors (e.g., TAL1. GATA proteins) and chromatin modifiers. It plays vital roles in embryonic blood vessel formation, erythropoiesis, and T-cell development. Dysregulation of LMO2 is strongly linked to T-cell acute lymphoblastic leukemia (T-ALL), where its aberrant expression drives oncogenic transcriptional programs.
In diagnostics, LMO2 antibodies are widely used in immunohistochemistry (IHC) to detect protein expression in tumor tissues. Notably, LMO2 is a biomarker for germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), aiding in subtyping and prognosis. High LMO2 expression in DLBCL correlates with better clinical outcomes. Additionally, research-grade antibodies facilitate studies of LMO2's role in normal hematopoiesis, angiogenesis, and leukemogenesis via techniques like Western blot, flow cytometry, and immunofluorescence.
Recent studies explore LMO2 as a therapeutic target, with antibodies enabling mechanistic insights into its interaction networks and downstream pathways. Its dual role in development and cancer underscores its biological and clinical significance.
×
